Alzheimer’s disease biomarker analysis using targeted mass spectrometry
Evidence
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.ABSTRACTAlzheimer's disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques),...
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPT
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.